Effects of on-treatment ALT flares on serum HBsAg and HBV RNA in patients with chronic HBV infection
Journal of Viral Hepatitis — Choi HSJ, Sonneveld MJ, Farag MS, et al. | September 14, 2021
ALT flares during PEGylated interferon-alpha (PEG-IFN-α) treatment are linked to subsequent HBsAg and HBV RNA decline and anticipate subsequent HBsAg loss. Flares occurred infrequently following PEG-IFN-α add-on therapy and were linked with low HBsAg loss rates. Combination regimens aimed at the window of heightened response have the potential to be effective.
It was a post hoc analysis of four international randomized trials.
For this trial, 269/130/124/128 patients on PEG-IFN-α monotherapy, PEG-IFN-α plus nucleos(t)ide analogue (NA) de novo combination, PEG-IFN-α add-on to NA, or NA monotherapy were involved, respectively.
In 83/651 (13%) patients (median timing/magnitude: week 8 [IQR 4-12], 7.6×ULN [IQR 6.2-10.5]), on-treatment flares occurred.
Flare patients were more likely to be Caucasians with genotype A/D, and they had greater baseline ALT, HBV DNA, HBV RNA, and HBsAg levels than the control group.
PEG-IFN-α monotherapy (18%) and PEG-IFN+NA de novo combination (24%) resulted in more flares than PEG-IFN-α add-on (2%) or NA monotherapy (1%).
On-treatment flares were significantly and independently linked to HBsAg and HBV RNA decreases ≥ 1 log10 at the final visit; declines began shortly before the flare and progressed to 24 weeks later.
On-treatment flares occurred in 16/22 (73%) of individuals who achieved HBsAg reduction.